Curioso. Veo que ahora solo me deja entrar a Value Line. Qué poco ha durado xD
Investigaré a ver…
¿Tendréis problemas por usar todos la misma dirección en USA?
¿Tendréis problemas por usar todos la misma dirección en USA?
Por qué? Somos un piso de estudiantes 
No será que se necesita un tiempo para que se sincronicen los datos entre la base de datos de la biblioteca y M*???
3 Me gusta
M* no tira pero el value line una pasada!!
Gracias!
Yo me registre en el 2107 N 5th Ave, Minneapolis, MN 55405
Por si alguno me quiere visitar 
8 Me gusta
Prepara comida y unas birras
2 Me gusta
He probado con otra biblioteca que tiene el mismo sistema, y con esta sí me funciona Morningstar.
La caducidad son 30 días. Pero puedes hacerte tantas cuentas como quieras… hasta que lo quiten 
Biblioteca de Santa Mónica:
https://smpl.org/ecard/
Registro en:
https://catalog.smpl.org/polaris/patronaccount/selfregister.aspx
Código postal: 90401
Dirección (cualquier en Santa Mónica, puedes usar la de la biblio…):
601 Santa Monica Blvd
Luego una vez loggeado, entras a Morningstar desde aquí:
http://research.smpl.org:2048/login?url=http://library.morningstar.com/
Y también tiene Value Line:
http://research.smpl.org:2048/login?url=http://www3.valueline.com/secure/vlispdf/stk1700/index.aspx
9 Me gusta
funciona perfecto!
1 me gusta
¿Soy yo o solo hay acceso a informacion de acciones americanas?
No estás solo. Para las europeas solo se puede consultar el ADR
Creo que hemos superado el numero de inquilinos
Thank you for registering with the Santa Monica Public Library!
We recently received your e-card registration online. In the online registration you entered 601 Santa Monica Blvd as your address. This is the Santa Monica Public Library address. Please provide a residential address.
Vente a vivir conmigo a Mineapolis 
1 me gusta
Probad con 3764 Elvis Presley Boulevard, Memphis, Tennessee
1 me gusta
Morningstar Dividend Yield Focus Index.
This index tracks the top 75 high-yielding stocks that meet our screening requirements for quality and financial health.
How are the index constituents chosen?
For starters, only securities whose dividends are qualified income are included; real estate investment trusts are tossed out. Companies are then screened for quality using the Morningstar Economic Moat and Morningstar Uncertainty ratings. Specifically, companies must earn a moat rating of narrow or wide and an uncertainty rating of low, medium, or high; companies with very high or extreme uncertainty ratings are excluded. We then screen for financial health using our distance-to-default measure, which uses market information and accounting data to determine how likely a firm is to default on its liabilities. The 75 highest-yielding stocks that pass the quality screen are included in the index, and constituents are weighted according to the total dividends paid by the company to investors.
Here are the index’s top 10 holdings as of the latest reconstitution in June 2020.
Seven of the stocks are undervalued by our metrics as of this writing.
Here’s a little bit from our analysts about the strength of the moats–and therefore the quality–for the seven undervalued names.
AT&T T
"Following the Time Warner acquisition, AT&T is truly a behemoth, with roughly $480 billion of invested capital employed in the business, or about $335 billion excluding goodwill. Its operations are now diversified across several distinct but interrelated businesses. AT&T’s grand strategy is to meld its consumer-facing telecom and media businesses into cohesive service offerings that attract and retain customers. We’re doubtful this plan will yield significant benefits. The telecom and media businesses are simultaneously mature and rapidly changing. We believe most consumers are generally aware of the wireless carriers’ strengths and weaknesses, choosing providers primarily based on service quality and price rather than add-ons or bundle options. We also expect the best content creators, including writers and actors, will migrate toward media firms that deliver the best mix of audience size and monetization potential over time. This dynamic should limit AT&T’s ability to overly restrict access to or discount the content it produces. Finally, AT&T’s scope should enable it to improve advertising yields, but we also expect changing consumer demands will force an offsetting reduction in ad loads across the traditional television market.
“Looking at AT&T’s businesses individually, we believe the firm still deserves a narrow moat based primarily on cost advantages within the wireless business and intangible assets acquired with Time Warner. These advantages should enable the firm to maintain relationships with customers and increase free cash flow. However, recent capital-allocation decisions have sharply lowered returns on invested capital. In aggregate, AT&T is a collection of businesses that should produce double-digit ROICs, but high acquisition prices will likely leave ROICs roughly in line with the firm’s cost of capital, as we calculate it, despite significant competitive advantages.”
–Mike Hodel, director
Exxon Mobil XOM
“We continue to rate Exxon Mobil as one of the higher-quality integrated firms, given its ability to capture economic rents along the oil and gas value chain. While its peers operate a similar business model with the same goal, they fail to do so as successfully, as evidenced in the lower margins and returns compared with Exxon. Exxon generates its superior returns from the integration of low-cost assets (an intangible asset that we consider to be part of its moat source) combined with a low cost of capital; this combination produces excess returns greater than those of its peers. However, given our outlook for lower long-term oil and natural gas prices, we expect Exxon’s returns to be lower than they have been in the past. Additionally, its decision to increase investment relative to peers during the next five years is also likely to narrow the gap in returns with peers. Consequently, our confidence that it can continue to deliver excess returns for longer is diminished, resulting in the company earning a narrow moat.”
–Allen Good, strategist
Chevron CVX
“Although Chevron is an integrated energy company, its narrow economic moat rests on the quality of its upstream portfolio. Chevron’s upstream segment holds a low-cost position based on an evaluation of its oil- and gas-producing assets, using our exploration and production moat framework. Its greater exposure to liquids and liquids-linked natural gas production has produced peer-leading cash margins during the past five years and resulted in returns on capital employed of nearly 20%, among the highest of the group. New production from its LNG projects Gorgon and Wheatstone, offshore oil developments in the Gulf of Mexico and West Africa, and tight oil growth should preserve this exposure. We forecast that Chevron can deliver a midcycle cash operating margin of nearly $30 per barrel of oil equivalent, the highest in its peer group.”
–Allen Good, strategist
Pfizer PFE
“Patents, economies of scale, and a powerful distribution network support Pfizer’s wide moat. Pfizer’s patent-protected drugs carry strong pricing power that enables the firm to generate returns on invested capital in excess of its cost of capital. Further, the patents give the company time to develop the next generation of drugs before generic competition arises. Additionally, while Pfizer holds a diversified product portfolio, there is some product concentration, with the company’s largest product Prevnar representing just over 10% of total sales. However, we don’t expect typical generic competition for the vaccine because of complex manufacturing and relatively low prices for the product. Further, we expect new products will mitigate the eventual generic competition of other key drugs. Also, Pfizer’s operating structure allows for cost-cutting following patent losses to reduce the margin pressure from lost high-margin drug sales. Overall, Pfizer’s established product line creates the enormous cash flows needed to fund the average $800 million in development costs per new drug. In addition, the company’s powerful distribution network sets up the company as a strong partner for smaller drug companies that lack Pfizer’s resources. Pfizer’s entrenched consumer and vaccine franchises create an added layer of competitive advantage, stemming from brand power in consumer healthcare and manufacturing cost advantages in the vaccines division. Pfizer recently created a consumer healthcare joint venture with GlaxoSmithKline that could lead to an eventual divestment of the unit, but the potential divestment shouldn’t have a material impact on the firm’s moat.”
–Damien Conover, director
Coca-Cola KO
“Numerous structural advantages should allow Coca-Cola to extract economic rents from the markets in which it competes, giving us confidence in awarding the firm a wide economic moat rating. At a high level, we believe there are characteristics endemic to the nonalcoholic beverage industry more generally, as well as Coca-Cola’s specific positioning within this industry, that result in a competitively advantaged business. While the company is disproportionately exposed to beverage categories that are in secular decline, we believe it has the brand equity to induce demand for reformulated variants of its most popular trademarks, the resources to reorient its portfolio toward drink categories that are more consistent with the consumer ethos, and the scale to fulfill these endeavors profitably.”
–Nicholas Johnson, analyst
Merck MRK
“Patents, economies of scale, and a powerful intellectual base buoy Merck’s business and keep it well shielded from the competition. As the bedrock of Merck’s wide moat, patent protection should continue to keep competitors at bay while the company strives to introduce the next generation of drugs. Further, the company’s enormous cash flows support a powerful salesforce that not only sells currently marketed drugs but also serves as a deterrent for developing drug companies seeking to launch competing products. As a result, Merck offers a powerful partnership opportunity for externally developed drugs. The cash flows also put the company in the rare position of supporting the approximately $800 million in research and development needed on average to bring each new drug to the market. While not as powerful as in the 1990s, Merck’s research laboratories still hold a vast database of knowledge that should help the company to maintain its leadership positions in drug discovery and development. Also, the company’s entrenchment in the emerging immuno-oncology area should strengthen Merck’s competitive position with drugs that carry very strong pricing power in areas of unmet medical need. Lastly, Merck’s strong entrenchment in vaccines adds a layer of competitive protection from intellectual property and cost advantages, as the firm’s large-scale production enables a lower cost base.”
–Damien Conover, director
PepsiCo PEP
“We believe several structural dynamics, centered on cost advantages and intangible assets, have solidified PepsiCo’s competitive positioning and secured it a wide economic moat. At a high level, we see characteristics of the snack and beverage categories where Pepsi competes, and its positioning within these categories, that should allow the company to continue to glean economic profits. While the firm’s integrated business models across food and beverages have pros and cons, we think the combination of diversity, synergy, and flexibility that they facilitate will allow Pepsi to maintain its standing even as its core categories face secular headwinds.”
–Nicholas Johnson, analyst
20 Me gusta
7 de las 10 en cartera, y la octava no tardara en caer.
2 Me gusta
10 de 10 con 3 teñidas de rojo (T, XOM, PFE)
4 Me gusta
Pego el artículo por si acaso lo hacen premium dentro de unos días
La Europe Large-Mid Cap Pick List es una lista de las acciones europeas más atractivas a nivel de valoración según Morningstar. La lista cubre las acciones de mediana y gran capitalización más infravaloradas del Índice Morningstar European Market Large-Mid Caps Index sobre una base ponderada por el sector y ajustada al riesgo. Esta lista no pretende ser una cartera modelo. La Europe Large-Mid Cap Pick List sirve como un generador de ideas para inversores con acciones prometedoras repartidas en varios sectores.
El índice Morningstar European Market Large-Mid Cap subió un 3,02% en junio. El índice está actualmente ligeramente infravalorado, ya que la relación precio / valor razonable indica un descuento del 6%. La infravaloración disminuyó ligeramente en comparación con el mes anterior, cuando fue del 9%.
Sobre una base relativa, la tecnología es ahora el sector más caro del Índice. El promedio de acciones tecnológicas cotiza con una prima del 31% sobre el valor razonable calculado por Morningstar. El sector energético sigue siendo el más barato y tiene un descuento del 48% en comparación con su valor razonable.
En cuanto a los componentes de nuestra lista, el descuento medio era, a finales de junio, de un 44% en comparación con el valor razonable. El sector más barato es el sector energético con un descuento promedio del 77% en comparación con el valor razonable.
Las nuevas incorporaciones a nuestra Europe Large-Mid Cap Pick List de este mes se pueden encontrar en los sectores de productos básicos ( HeidelbergCement ), bienes de consumo cíclico, ( Daimler ), consumo defensivo ( Henkel ), salud ( Grifols ) y servicios públicos ( Naturgy Energy Group ) con un valor en cada uno. Destacamos las siguientes incorporaciones.
6 Me gusta
No deja de ser sorprendente que un “dividend yield focus index” tenga cabida para un dividendo de tan solo el 2.84%
2 Me gusta
T y XOM muy endeudadas, PFE desde hace 5 años que no va a ningún lado.
1 me gusta
JNJ también tuvo una década perdida cotizando a cincuenta y tantos / sesenta y tantos USD. Que no significa que PFE vaya a hacer lo mismo, claro.
Que conste, que yo también llevo en cartera PFE.